Russell Maxwell1, Andrew S Luksik1, Tomas Garzon-Muvdi1, Michael Lim2. 1. Department of Neurosurgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Neurosurgery - Phipps 123, Baltimore, MD, 21287, USA. 2. Department of Neurosurgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Neurosurgery - Phipps 123, Baltimore, MD, 21287, USA. mlim3@jhmi.edu.
Abstract
PURPOSE OF REVIEW: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses. RECENT FINDINGS: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.
PURPOSE OF REVIEW: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses. RECENT FINDINGS: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.
Entities:
Keywords:
Adoptive cell transfer; CAR T cells; Dendritic cell vaccines; Glioma; Immunotherapy; Oncolytic virus
Authors: K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia Journal: J Neurooncol Date: 1999 Impact factor: 4.130
Authors: Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal Journal: Mol Ther Date: 2005-10-28 Impact factor: 11.454
Authors: Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau Journal: Clin Cancer Res Date: 2010-12-06 Impact factor: 12.531
Authors: Sabrina Genßler; Michael C Burger; Congcong Zhang; Sarah Oelsner; Iris Mildenberger; Marlies Wagner; Joachim P Steinbach; Winfried S Wels Journal: Oncoimmunology Date: 2015-12-21 Impact factor: 8.110
Authors: Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Ming Yang; Gregory Christoforidis; Giulia Fulci; Fred H Hochberg; Ralph Weissleder; William Carson; E Antonio Chiocca; Balveen Kaur Journal: J Natl Cancer Inst Date: 2007-11-27 Impact factor: 13.506
Authors: Surasak Phuphanich; Christopher J Wheeler; Jeremy D Rudnick; Mia Mazer; Hongqian Wang; Miriam A Nuño; Jaime E Richardson; Xuemo Fan; Jianfei Ji; Ray M Chu; James G Bender; Elma S Hawkins; Chirag G Patil; Keith L Black; John S Yu Journal: Cancer Immunol Immunother Date: 2012-07-31 Impact factor: 6.968
Authors: Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp Journal: Oncology (Williston Park) Date: 2019-03-13 Impact factor: 2.990